Novo Nordisk and Septerna have announced a global collaboration to develop oral small molecule medicines targeting obesity, type 2 diabetes, and other cardiometabolic diseases.
On May 2, Aktiia, a blood pressure intelligence platform, announces an oversubscribed $42 million Series B funding round, co-led by Earlybird Health and Wellington Partners